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increase in end-diastolic pressure. Using simultaneous Doppler echo- 
cardiographic%d apexcardiographic recordings, we have previously 
reported (3,4) that in patients with coronary and hypertensive heart 
disease, a decreased peak A flow velocity is most frequently associated 
with a significantly elevated apexcardiographic A wave height. Accord- 
ing to our data, atria1 systolic function, which is given by the “gener- 
ation of pressure” and assessed by the relative height of the apexcar- 
diographic A wave, is not decreased but significantly increased in such 
patients. Consequently, the decrease in flow through the mitral valve 
during atria1 contraction in this clinical setting does not reflect a 
diminished power of atrial contraction; rather. it is the result of 
elevated ventricular tilling pressures only. Thus, “true atria1 function” 
can be evaluated only by an additional assessment of the power of 
“pressure generation” and the resulting “atrial kick” by the use of 
apexcardiographic recordings. These alternative fundamental patho- 
physiologic aspects, which have been extensively analyzed by many 
investigators using various techniques, were entirely neglected by 
Manning et al. By excluding these important data from the interpre- 
tation and discussion of their findings, the authors arrived at false 
conclusions about the nature and definition of atria1 function itself. 
A combined Doppler echocardiographic and apexcardiographic A 
wave index would probably help greatly in providing a clinically useftil 
evaluation of “true atrial function.” Such an index could be. for 
example, the ratio of the relative A wave to total height of apexcar- 
diogram and the peak A flow velocity; the former provides information 
about the force of “pressure generation” and the latter about the 
“change in flow” during atrial contraction. 
We hope that our previous work using both Doppler (flow) and 
apexcardiographic (pressure) A waves will stimulate the development 
of such combined indexes for accurately evaluating the “true atrial 
function and performance,” which can only be assessed when both 
parts of the equation are given. 
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In our report (1) we define atlial ejection force as “that force exerted 
by the left atrium in propelling blood into the left ventricle during 
atria1 systole . . . and should not be misinterpreted as an assessment of 
‘total’ atrial force.” Total atrial force would be the vector sum of all 
forces acting within the atrium. Utilizing echocardiographic variables, 
atrial ejection force is prc=ortional to peak A velocity squared. 
We agree that peak A velocity is frequently elevated among 
patients with heart disease. Because pe%k A velocity may be increased 
among patients with coronary and hypertenswe heart disease, one 
would then have expected atria1 ejection force to be increased in the 
study group (compared with control subjects), yet it was significantly 
depressed after cardioversion and continued for at !east I week after 
cardioversion. With each patient used as their own control, atrial 
ejection force significantly increased during the succeeding period of 
observation. To explain our findings on the basis of changes in filling 
pressure alone, one wuiild ha-e to hypothesize that left atrial filling 
pressure increased during the month after cardioversion. It is more 
likely that filling pressures declined (2). Thus, through the use of 
longitudinal data, we are comfortable in aarming the validity of atrial 
ejection force as an index of atria1 systolic function. We are unaware of 
serial apexcatdiogtaphic data among patients undergoing cardiover- 
sion and cannot be certain how this variable would change. Because 
the height of the apexcardiographic A wave is more closely related to 
ventricular stiffness, end-diastolic pressure and the volume 0: atrial 
sys!olic flow, concordance between it and atrial ejection force may be 
limited. 
We fully appreciate that “transmitral Doppler data alone do not 
fully reflect changes in ventricular compliance and . . a less compliant 
ventricle might present greater resistance to transmitral inflow and 
result in a depressed peak A wave velocity” (1). Better models are 
indeed needed, but because of the complexity of left ventricular 
diastolic and left atrial systolic function, one must carefully identify 
which components of cardiac performance are being assessed. 
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IIeparin and Aspirin in Unstable Angina: 
Insuficient Sample Size May Lead to 
Erroneous Conclusions 
In their article, Holdright et al. (1) address the interesting question 
whether, in patients with unstable angina, heparin combined wifh 
apirin is more effective in preventing transient myocardial ischemia 
than aspirin alone. The authors attack the current standard of practice 
in the United States, which is to use both aspirin and heparin (2). The 
authors, therefore. have the burden of proof. 
Holdright et ai. conclude that ‘-combined therapy with heparin and 
aspirin compared with aspirin aione makes no difference in the 
development of [transient myocardial ischemia].” Strikingly. their data 
shown in Table 2 (1) suggest just the opposite. The number of patients 
with at least one episode of transient mycc&rdial ischemia was 2% less 
in the heparin plus aspirin group than in the aspirin alone group, 18% 
vs. 24% of patients, respectively. Even more strikingly, this pattern was 
consistent in every single variable presented by the authors. The total 
number of episodes in the heparin plus aspirin group was less by 354, 
the median duration of episodes shorter by 16%; the total duration of 
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ischemia by 4!% (!), the number of patients with 160 min of transient 
myocardial ischemia decreased by 10% and silent episodes by 5%. 
These data ail suggest a reduction in transient rnyocardial ischemia 
when heparin is added to aspirin. However, the differences did not 
reach statistical significance, probably because of the small sample stze. 
The authors speculate “that 260 patients would be needed to give 
sufficient power (85%) to show a 70% reduction in transient myocar- 
dial ischemia.” According to our calculations, to achieve a similar 
power to show a more realistic 25% reduction, a sample size of 910 
patients would have been needed. The authors’ own data actually do 
suggest a reduction of this magnitude. In our opinion, to expect a 70% 
reduction in ischemia incidence from the addition of heparin to 
aspirin, a treatment modality in itself of proved efficacy, was quite 
unrealistic. 
Too small a sample size in randomized controlled trials having 
negative results seems to be a common error according to data 
published recently in JAMA (3). Of 102 such studies, only 16% and 
36% had sufficient statistical power to detect a 25% or SO% relative 
difference, respectively. 
We believe that the authors’ data do not support their conclusion 
that heparin plus aspirin is no more effective than aspirin alone in 
unstable angina pectoris. In fact, their data suggest but do not prove 
that heparin plus aspirin is more effective. To draw defnitive conclu- 
sions, a substantially bigger study involving -1,000 patients would be 
required. 
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Bode ct al. raise a point that should be asked when any compartson of 
different treatment strategies indicates the treatment modalities in 
question to be the same with respect to predefined end points. They 
suggest that an inadequate sample size may be responsible for our 
finding that combination therapy with heparin and aspirin was no 
different than aspirin alone in reducing the incidence of transient 
myocardial ischaemia in patients with unstable angina. We welcome 
the opportunity to defend our sample size calculation. 
The sample size was based on the expected incidence of transient 
myocardial ischemia and the effects of heparin and aspirin on transient 
myocardial ischemia. We indicated in the report that the calculations 
were made on the basis of data from the study by Semeri et al. (1) in 
which the etfects of heparin, aspirin and alteplase on myocardial 
iachcmia were compared in patients with unstable angina. Using 
continuous ST segmen: Iloiter monitoring they compared the effects 
of these treatments on the frequency of angina, number of silent 
ischemic episodes, total number of ischemic episodes and total dura- 
tion of ischemia. Their results indicated that treatment with heparin 
reduced angina1 episodes by 94%, silent ischemjc episodes by 71% 
total ischemic episodes by 78% and tota: duration of ischemia by 81% 
In contrast, aspirin had no significant effect. The typical odds reduction 
for recurrence of angina with heparin versus other treatments was 66% 
(SD 6.4%) for days 0 to 3 (p < 0.0013). On the basis of these results 
we believe that our original power calculation was reasonable. We 
estimated that 260 patients would be required to show a 70% reduction 
in transient myocardial ischemia with heparin and aspirin compared 
with aspirin alone, assuming a 20% incidence of transient ischemia in 
patients treated with aspirin, giving a power of 85%. Because some 
patients will be included who, in retrospect, will be diagnosed as having 
myocardial infarction, we increased the sample size by a further 10%. 
We believe that it is reasonable to expect a 70% reduction in ischemia 
with the addition of heparin because that is supported by the data from 
Serneri et al. (1). 
As Bodo et al. indicate, the sample size of any trial should be 
carefully inspected, but they should not be drawn into making state- 
ments about treatment guidelines by interpreting data “trends” when 
statistical significance is not reached. For example, they make several 
comments about the data in Table 2 from which they suggest that 
combination therapy is superior to aspirin. To state that the number of 
patients with transient myocardial ischemia was 25% less in the 
combination group is misleading when the absolute numbers of 
patients were 31 in the aspirin group versus 27 in the heparin and 
aspirin group-a difference of 4 patients. Similariy, tile other variables 
mentioned by Bodo et al. are particularly influenced by one patient in 
the aspirin group who r‘lntributed 1,360 min of transient ischemia, 
which constituted >25Y~ of the total ischemia in that group. We high- 
lighted the point in the text of our article. Consequently, we believe that 
Bodo et al. have no basis for suggesting that our data indicate that heparin 
and aspirin therapy is superior to aspirin alone. 
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Early Repair of Tetralogy of Fallot and 
Ventricular Arrhythmia 
It has been suggcstsd that in patients with tetralogy of Faliot, 
occurrence of late ventricular arrhythmias and possibly sudden death 
would decrease if surgical correction is performed early in life. The 
work of Joffe et al. (I) has attempted to address this important issue. 
This study describes the iong-term follow-up results in 29 patients after 
repair of tctraiogy of Fallot. 
“Early” versus “late” repair of tetralogy of Fallot is not clearly 
defined in published reports. Nevertheless, “early” commonly implies 
complete repair at the time of, or even before, development of the 
need for palliative surgery. which usually occurs during the first year of 
